Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alutard SQ Felis domesticus is a standardized allergen extract derived from the hair and dander of the domestic cat (*Felis domesticus*), specifically formulated for allergen immunotherapy (AIT). Developed by ALK-Abelló, it utilizes the Standardized Quality (SQ) system to ensure potency and consistency of the major allergen, Fel d 1. The product consists of allergens adsorbed onto aluminum hydroxide, which serves as an adjuvant to create a depot effect, facilitating the slow release of the allergen and reducing the risk of systemic allergic reactions. Its mechanism of action involves the induction of immune tolerance, shifting the immune response from a Th2-mediated allergic phenotype (associated with IgE production) to a Th1/Treg-mediated response (characterized by the production of allergen-specific IgG4 antibodies and the suppression of mast cell and basophil activation). It is primarily indicated for the treatment of patients with IgE-mediated allergic rhinitis and allergic asthma triggered by cat allergens. While traditionally administered via subcutaneous immunotherapy (SCIT), it is also being investigated for intralymphatic immunotherapy (ILIT) to potentially improve safety and reduce treatment duration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alutard SQ Felis domesticus.